Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection
Tengfang Li, … , Stephen F. Badylak, Hēth R. Turnquist
Tengfang Li, … , Stephen F. Badylak, Hēth R. Turnquist
Published July 9, 2020
Citation Information: J Clin Invest. 2020;130(10):5397-5412. https://doi.org/10.1172/JCI133008.
View: Text | PDF
Research Article Immunology

Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection

  • Text
  • PDF
Abstract

Alarmins, sequestered self-molecules containing damage-associated molecular patterns, are released during tissue injury to drive innate immune cell proinflammatory responses. Whether endogenous negative regulators controlling early immune responses are also released at the site of injury is poorly understood. Herein, we establish that the stromal cell–derived alarmin interleukin 33 (IL-33) is a local factor that directly restricts the proinflammatory capacity of graft-infiltrating macrophages early after transplantation. By assessing heart transplant recipient samples and using a mouse heart transplant model, we establish that IL-33 is upregulated in allografts to limit chronic rejection. Mouse cardiac transplants lacking IL-33 displayed dramatically accelerated vascular occlusion and subsequent fibrosis, which was not due to altered systemic immune responses. Instead, a lack of graft IL-33 caused local augmentation of proinflammatory iNOS+ macrophages that accelerated graft loss. IL-33 facilitated a metabolic program in macrophages associated with reparative and regulatory functions, and local delivery of IL-33 prevented the chronic rejection of IL-33–deficient cardiac transplants. Therefore, IL-33 represents what we believe is a novel regulatory alarmin in transplantation that limits chronic rejection by restraining the local activation of proinflammatory macrophages. The local delivery of IL-33 in extracellular matrix–based materials may be a promising biologic for chronic rejection prophylaxis.

Authors

Tengfang Li, Zhongqiang Zhang, Joe G. Bartolacci, Gaelen K. Dwyer, Quan Liu, Lisa R. Mathews, Murugesan Velayutham, Anna S. Roessing, Yoojin C. Lee, Helong Dai, Sruti Shiva, Martin H. Oberbarnscheidt, Jenna L. Dziki, Steven J. Mullet, Stacy G. Wendell, James D. Wilkinson, Steven A. Webber, Michelle Wood-Trageser, Simon C. Watkins, Anthony J. Demetris, George S. Hussey, Stephen F. Badylak, Hēth R. Turnquist

×

Figure 3

Increased iNOS+ inflammatory myeloid cells cause vasculopathy in IL-33–deficient heart transplants.

Options: View larger image (or click on image) Download as PowerPoint
Increased iNOS+ inflammatory myeloid cells cause vasculopathy in IL-33–d...
(A–D) Leukocytes infiltrating Il33+/+ or Il33–/– Bm12 grafts transplanted into WT B6 recipients (n = 6–7/group) were assessed by flow cytometry on POD 3. Leukocytes from naive Bm12 hearts were included as baseline controls (n = 4). (A) Representative plots of monocyte-derived dendritic cells (monoDCs) in the CD45.2+ gate. (B) Frequency of CD11b+CD11c+ and CD11b+CD11c+MHCIIhi cells in the CD45.2+ gate. (C) Representative plots of macrophage subsets in the CD45.2+CD11c–CD11b+ gate. (D) Frequency of F4/80+Ly6Chi, F4/80+Ly6Clo, and F4/80+Ly6ChiMHCIIhi macrophages in the CD45.2+CD11c–CD11b+ gate. (E) Representative fluorescent immunolabeling for iNOS (green) and CD11b (orange) and staining with DAPI (blue) in Il33+/+ (left panel; n = 5) or Il33–/– (right panel; n = 6) Bm12 heart transplants into WT B6 recipients at POD 30. Scale bars: 100 μm. (F) Quantification of percentage iNOS+CD11b+ and percentage CD11b+DAPI+ cells. Graphs depict 3 to 5 values for randomly selected regions from each transplant sample and group mean ± SD. (G and H) Il33+/+ or Il33–/– Bm12 grafts were transplanted into B6 WT or Ccr2–/– recipients (n = 3–7/group). (G) Grafts harvested on POD 30 were evaluated after Masson’s trichrome staining for vasculopathy. Scale bars: 100 μm. (H) Percentage vascular occlusion was quantified, and graphs depict individual values and group mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001 by 1-way ANOVA (B, D, and H) or 2-tailed t test with Welch’s correction (F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts